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Introduction: Elevated type I interferon (IFN) response gene (IRG) expression has proven clinical relevance in
predicting rituximab non-response in rheumatoid arthritis (RA). Interference between glucocorticoids (GCs) and type
I IFN signaling has been demonstrated in vitro. Since GC use and dose are highly variable among patients before
rituximab treatment, the aim of this study was to determine the effect of GC use on IRG expression in relation to
rituximab response prediction in RA.
Methods: In two independent cohorts of 32 and 182 biologic-free RA patients and a third cohort of 40
rituximab-starting RA patients, peripheral blood expression of selected IRGs was determined by microarray or
quantitative real-time polymerase chain reaction (qPCR), and an IFN-score was calculated. The baseline IFN-score
was tested for its predictive value towards rituximab response in relation to GC use using receiver operating
characteristics (ROC) analysis in the rituximab cohort. Patients with a decrease in disease activity score (ΔDAS28) >1.2
after 6 months of rituximab were considered responders.
Results: We consistently observed suppression of IFN-score in prednisone users (PREDN+) compared to
non-users (PREDN−). In the rituximab cohort, analysis on PREDN− patients (n = 13) alone revealed improved
prediction of rituximab non-response based on baseline IFN-score, with an area under the curve (AUC) of 0.975
compared to 0.848 in all patients (n = 40). Using a group-specific IFN-score cut-off for all patients and PREDN−
patients alone, sensitivity increased from 41% to 88%, respectively, combined with 100% specificity.
Conclusions: Because of prednisone-related suppression of IFN-score, higher accuracy of rituximab response
prediction was achieved in PREDN− patients. These results suggest that the IFN-score-based rituximab response
prediction model could be improved upon implementation of prednisone use.Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease characterized by chronic joint inflammation which
may lead to cartilage and bone destruction. It is a heteroge-
neous disease, as reflected by differences in severity, patho-
genesis and treatment outcome. From diagnosis onwards,
RA patients often receive immunosuppressive treatment
with non-biologic disease-modifying anti-rheumatic drugs* Correspondence: c.verweij@vumc.nl
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stated.(DMARDs) and/or glucocorticoids (GCs). When patients
no longer benefit from the non-biologic therapy, they usu-
ally start on treatment with biologics, such as TNFα-
blockers and B-cell depletion therapy using rituximab
(RTX) [1]. Approximately 30% to 50% of patients do not
achieve a favorable response to biologics. To increase treat-
ment efficacy and to develop personalized treatment, pre-
dictors of therapy response are needed.
Independent studies have shown that activation of the
type I interferon (IFN) system is associated with the clin-
ical outcome of RTX therapy [2,3]. This so-called ‘IFN
signature’ represents a response program consisting of
genes that are activated by type I IFNs and is present in
approximately 50% of RA patients [4]. Induction of typel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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the JAK-STAT signaling pathway, more specifically via
JAK1, TYK2, STAT1 and STAT2, followed by recruit-
ment of IRF9 and formation of the ISGF3 transcription
factor complex [5]. It was shown that patients with a
good response to RTX have low IRG expression prior to
the start of treatment, whereas non-responders display
relatively high IRG expression. Potential clinical utility of
IRG expression reflected as an IFN-score to predict the
clinical outcome of RTX treatment was demonstrated by
an area under the receiver operating characteristics
(ROC) curve of 87% [3]. Hence, knowledge of IRG ex-
pression in a RA patient before the start of RTX treat-
ment is of crucial importance to predict the success of
the clinical outcome.
It has been reported that GCs can interfere with the
type I IFN system by modulation of IFN induction as well
as downstream IFN signaling [6,7]. GCs were initially pre-
scribed to RA patients in high doses (≥10 mg/day) to sup-
press flares of inflammation, but nowadays long-term
treatment with low-dose GCs is commonly used as well
[8]. Since use and dose of GCs are highly variable among
patients prior to the start of treatment with RTX [2,3], we
aimed to determine what the effect of GC use is on IRG




Age, years 49 ± 10
Female, number (%) 22 (69)
Disease characteristics
Disease duration, years 7.5 ± 8.9
Disease activity (DAS28) 5.4 ± 1.3
ESR, mm/hour 29.3 ± 22.2
CRP, mg/L 18.8 ± 19.4a
Erosions, number (%) 24 (75)
IgM RF positive, number (%) 28 (88)
ACPA positive, number (%) 26 (87)b
Medication
Current prednisone use, number (%) 6 (19)
Prednisone dosage, mg/day 8 ± 2
Current MTX use, number (%) 25 (78)
MTX dosage, mg/week 21.2 ± 7.1
Current SSZ use, number (%) N/A
Current HCQ use, number (%) N/A
aData missing for 7 of the 32 patients; bdata missing for 2 of the 32 patients; cdata
Continuous variables are presented as mean with standard deviation. ACPA, anti-cy
sedimentation rate; HCQ, hydroxychloroquine; MTX, methotrexate; N/A, not applicaMethods
Patients
This study consisted of three independently collected
cohorts. All patients fulfilled the revised American
College of Rheumatology (ACR) 1987 criteria for RA diag-
nosis [9]. Patient characteristics are shown in Table 1.
Cohort I included 32 RA patients of whom 6 patients
were treated with the GC prednisone, as previously
reported [4]. Cohort II was recruited from Jan van
Breemen Research Institute | Reade, Amsterdam, the
Netherlands, and consisted of 182 RA patients, of
whom 52 patients received prednisone. The patients in
these two cohorts had not been on any biologic treat-
ment. Cohort III was recruited from Jan van Breemen
Research Institute | Reade and the VU University
Medical Center, Amsterdam, the Netherlands, and con-
sisted of 40 RA patients, of whom 27 patients were
using prednisone [3]. These 40 patients were candidates
for RTX therapy because of their high disease activity
(disease activity score in 28 joints (DAS28) >3.2) despite
DMARD treatment and previous anti-TNF therapy. At
the moment of blood collection, patients were off anti-
TNF therapy for at least four weeks and had not re-
ceived their first RTX dose yet. The clinical response to
RTX was determined based on the change in DAS28Cohort II Cohort III (rituximab)
Number = 182 Number = 40
54 ± 12 57 ± 10
135 (75) 34 (85)
9.5 ± 10.2 11.0 ± 9.5
5.1 ± 1.2 5.8 ± 1.1
24.5 ± 18.0 29.2 ± 23.8
17.8 ± 22.1 17.7 ± 17.7
131 (72) 28 (72)
130 (71) 27 (68)
129 (75)c 29 (73)
52 (29) 27 (68)
7.2 ± 3.5 6.75 ± 6.0
152 (84) 26 (65)
21.0 ± 6.3 18.7 ± 8.2
27 (16)d 7 (18)
35 (20)d 5 (13)
missing for 9 of the 182 patients; ddata missing for 9 of the 182 patients.
clic citrullinated protein antibody; CRP, C-reactive protein; ESR, erythrocyte
ble;RF, rheumatoid factor; SSZ, sulphasalazine.
Figure 1 Effect of prednisone use on IFN-score in cohort I.
In peripheral blood of 32 RA patients, gene expression levels of 7
interferon response genes were averaged to calculate the IFN-score.
The IFN-score was evaluated in relation to prednisone use;
prednisone-treated patients (PREDN+) exhibited a lower IFN-score than
prednisone-untreated patients (PREDN−). RA, rheumatoid arthritis.
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were considered responders [10]. All patients provided writ-
ten informed consent and the participating clinics received
approval by the medical ethics committees of the Academic
Medical Center, the VU University Medical Center and the
Jan van Breemen Research Institute | Reade.
RNA isolation
Blood was collected in a PAXgene tube (PreAnalytix,
Hombrechtikon, Switzerland) and frozen at −20°C until
RNA isolation. Total RNA was isolated using the PAXgene
blood RNA isolation kit according to the manufacturer’s
protocol. RNA quantity and purity was determined using
the Nanodrop spectrophotometer (Nanodrop Technolo-
gies, Wilmington, DE, USA). In case of subsequent quanti-
tative (q)PCR measurements, RNA was converted to
cDNA using the Revertaid H-minus cDNA synthesis kit
(MBI Fermentas, St. Leon-Rot, Germany), according to
the manufacturer’s protocol.
Gene expression measurements and calculation of the
IFN-score
The IFN-score was calculated as the mean of the log2-
transformed expression values of a set of IRGs for an in-
dividual patient. A set of eight correlative IRGs (EPSTI1,
HERC5, IFI44L, ISG15, LY6E, MX1, MX2 and RSAD2),
previously shown to be predictive for the response to
RTX [3], was measured, unless indicated otherwise. IRG
expression levels were determined by DNA microarray,
multiplex qPCR (Fluidigm Corporation, San Francisco,
CA, USA) or conventional qPCR (ABI Prism 7900HT,
Applied Biosystems, Foster City, CA, USA). To combine
microarray and qPCR data, data were median-centered
as described previously [3].
Statistical analysis
Based on data normality, comparison of two groups was
performed using the Student’s unpaired t-test or Mann–
Whitney U test. Comparison of multiple groups was per-
formed using one-way analysis of variance (ANOVA),
Kruskal-Wallis one-way ANOVA or χ2-test, where ap-
propriate. ROC analyses were performed using non-
responder status defined as dDAS28 < 1.2 as the state
variable. All analyses were performed using IBM SPSS
Statistics version 20.0 (IBM Corp, Armonk, NY, USA).
P values <0.05 were considered to be significant.
Results
Patient characteristics
Demographic and clinical data are shown in Table 1.
Whereas cohorts I and II were not significantly different
except for age (P = 0.024), there was a significant in-
crease in disease activity, prednisone use and prednisone
dose in cohort III (comparison of all three cohorts, P =0.007, P <0.001 and P <0.001 respectively), probably il-
lustrating the more severe disease state in these patients,
as expected. Methotrexate (MTX) use was lower in co-
hort III compared to cohorts I and II. No significant dif-
ferences in clinical parameters were observed in any of
the cohorts between prednisone users and prednisone
non-users.Prednisone treatment and type I IFN response gene
expression
To evaluate whether prednisone use affects the type I
IFN-score in RA, we initially tested the relation between
prednisone use and the IFN-score in patients of cohort I.
Thereto, we assessed IRG expression from available
microarray data [4]. Since the HERC5 gene was not avail-
able on the microarray at that time, the IFN-score was
based on seven IRGs. This analysis revealed a difference
between the IFN-score and prednisone use; the IFN-score
was lower in PREDN+ patients compared to PREDN− pa-
tients (P = 0.053, Figure 1).
To validate the findings from cohort I, we compared
the IFN-scores between PREDN− and PREDN+ patients
in an independent cohort consisting of 182 RA patients
(cohort II). This confirmed our earlier findings, showing
a significantly lower IFN-score in PREDN+ patients
compared to PREDN− patients (P = 0.028, see Figure 2A).
Overall, these findings reveal a relation between prednis-
one use and a low IFN-score.
In addition to variation in prednisone use itself, the dose
of prednisone varied between users, from 2.5 mg/day to
20 mg/day. Therefore, we also compared prednisone dose
and IFN-score. As shown in Figure 2B, the range of the
IFN-score gradually decreased with increasing prednisone
Figure 2 Effect of prednisone on the IFN-score validated in cohort II. In peripheral blood of 182 RA patients, gene expression levels of 8
interferon response genes were averaged to calculate the IFN-score. The IFN-score was evaluated in relation to prednisone use and prednisone
dose. A) Comparison of IFN-score between prednisone-untreated (PREDN−) and prednisone-treated (PREDN+) RA patients; B) The relation
between prednisone dose and IFN-score, assessed using Kruskal-Wallis. RA, rheumatoid arthritis.
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dependent. The decrease in IFN-score was most pro-
nounced at the highest doses of 10 mg/day or more
(Kruskal-Wallis, P = 0.041).Effect of prednisone treatment on the predictive value of
the IFN-score in the outcome of rituximab treatment
The above results indicate that prednisone use is associ-
ated with a lower IFN-score in RA. We reasoned that
the suppressive effect of prednisone on the IFN-score
could have implications for the clinical utility of the
IFN-score as predictor for the outcome of RTX therapy
in RA. Therefore, we studied the relation between pred-
nisone use and the predictive value of the IFN-score in a
cohort of 40 RA patients who were candidates for RTX
therapy (Cohort III).
The predictive value towards the clinical response to
RTX was determined for the eight-IRG-based IFN-score,
as well as for the IFN-score based on three IRGs
(EPSTI1, MX1 and RSAD2), which was previously de-
scribed to give the most optimal performance as a pre-
dictor of RTX response [3]. As described before, no
association of prednisone use itself as predictor for the
outcome of RTX treatment was found in this cohort
(odds ratio (OR):2.0, 95% confidence interval (CI):0.49 to
8.20, P = 0.335 [3]). As a measure of accuracy of the
IFN-score in separating responders and non-responders,
we performed ROC analysis on the whole group (n = 40,
18 responders, 22 non-responders), the PREDN+ group
(n = 27, 13 responders, 14 non-responders) and PREDN−
group (n = 13, 5 responders, 8 non-responders).
For the eight-IRG set, the group as a whole showed an
area under the curve (AUC) of 0.828, which is consid-
ered very good. The group of PREDN+ patients alone re-
vealed an AUC of 0.758 which is less than observed for
the whole group. For the PREDN− patients, the AUC
reached an excellent value of 0.950 (Figure 3A).The same ROC analyses for the optimally performing
three-IRG set revealed an AUC of 0.797 in the PREDN+
group, again less than the AUC of 0.848 that was observed
for the whole group. The PREDN− group reached an AUC
of 0.975, which is equivalent to an excellent prediction
(Figure 3B). At an IFN-score cutoff with a specificity of
100%, this corresponds to a sensitivity of 88% in the
PREDN− group, compared to a sensitivity of 41% in the
whole group (Figure 4A). These findings indicate that
stratification on prednisone use before measuring the ex-
pression of IRGs to predict the clinical outcome of RTX
treatment could dramatically improve the predictive
power of the test.
A detailed analysis of the enhanced AUC in the
PREDN− group revealed that the improved prediction of
RTX response is a consequence of a larger difference in
IFN-score between responders and non-responders in
the PREDN− group, together with improvement of the
IFN-score cut-off value. When using the IFN-score cut-
off yielding 100% specificity in the whole group, the
PREDN− group already displayed an improved sensitivity
of 63%, compared to the original 41% sensitivity of the
whole group (Figure 4A). When the IFN-score cut-off
was selectively determined for the PREDN− group, sensi-
tivity in this group was even further enhanced to 88%
(Figure 4A and 4B). Altogether, stratification for prednis-
one use in this cohort resulted in the correct classification
of 100% of the responders and 50% of all non-responders
(7/8 non-responders in the PREDN− group and 4/14 non-
responders in the PREDN+ group), compared to 100% of
responders and 41% of the non-responders (9/22 non-
responders) without stratification.
Discussion
Previous studies have shown that the IFN-score has clin-
ical relevance by predicting the outcome of RTX therapy;
a high IFN-score reflecting increased IRG expression at
baseline is associated with a poor clinical response to RTX
Figure 3 ROC analyses of rituximab response prediction in cohort III. The predictive value of the IFN-score for the outcome of rituximab
treatment was assessed per patient subgroup based on prednisone treatment. A) ROC analysis for the eight-IRG set; B) ROC analysis for the highly
predictive three-IRG set. IRG, interferon response gene; ROC, receiver operating characteristics.
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age IFN-score was consistently lower in prednisone-using
patients compared to patients not using prednisone. As a
consequence, RTX response prediction based on the IFN-
score was considerably improved when stratifying patients
based on prednisone use. ROC analysis of the PREDN−
group based on an IFN-score of three IRGs yielded an al-
most perfect AUC of 0.975, compared to 0.848 and 0.797
in all patients or prednisone users alone, respectively.
This means that a test based on the three-IRG IFN-
score would correctly classify 98% of two PREDN− pa-
tients of two randomly drawn pairs, which is considered
‘excellent.’ Based on these data, non-response to RTX
could be predicted with a specificity of 100% and a sen-
sitivity of 88% in PREDN− patients.
At the moment, the IFN-score-based RTX prediction
model seems to be the most discriminative test for RTXFigure 4 Subgroup-specific cut-offs for rituximab prediction. Detailed
stratification for prednisone use. A) Sensitivities of rituximab response prediction
the IFN-score, based on the ROC analyses per subgroup; B) IFN-scores per respo
specificity are indicated with the dotted lines and are 1.36 for all patients and th
ROC, receiver operating characteristics.response prediction and has already demonstrated
clinical utility [3,11]. The current data show that the
model could be further optimized via stratification for
prednisone use. GC therapy has proven to be a vital
part in the management of RA [1] and is often pre-
scribed as bridging therapy in between biologics to
prevent or suppress inflammatory flares. The observa-
tion that the RTX response prediction reached optimal
predictive value in patients without current prednisone
treatment suggests that the prednisone-related sup-
pression of the IFN-score obscures the ‘genuine’ intrin-
sic IRG expression, leading to the lower accuracy of
prediction. Since elimination of prednisone use in RA
patients would be practically intolerable, implementa-
tion of prednisone use and/or dose into the IFN-score-
based prediction model might be an approach to optimize
prediction of treatment outcome. Eventually, it might beanalysis of the improvement in rituximab response prediction upon
combined with 100% specificity, when using subgroup-specific cut-offs of
nder group and treatment subgroup. Subgroup-specific cut-offs for 100%
e PREDN+ patients, and 0.48 for the PREDN− patients. PREDN, prednisone;
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ment to measure the ‘genuine’ intrinsic IRG expression to
predict the response to RTX treatment, if the clinical con-
dition of the patient allows that. The current data provide
the first indication of the effect of medication history on
response prediction. The study consisted of cross-
sectional data and results need to be confirmed in a larger
prospective cohort of RA patients who are sampled before
and after GC treatment. Moreover, besides medication
history, the influence of cumulative dosing and term of
prednisone treatment should also be analyzed.
Our findings on the in vivo suppressive effect of prednis-
one on IRG expression in RA corroborates results from
mechanistic studies that reported an effect of GCs on the
type I IFN system. In systemic lupus erythematosus (SLE),
methylprednisolone injection coincided with a decrease in
plasmacytoid dendritic cells (pDCs), which are considered
to be the main producers of IFNα in SLE [12,13]. In RA,
evidence is available for a role of both IFNα and IFNβ
[14,15], indicating a broader cellular origin for these IFNs,
making it unlikely that the prednisone-related IRG sup-
pression in RA is caused solely by a decrease in pDCs.
Since GCs are able to interfere with the IRF3 and IRF9
pathways, thereby affecting IFNα/β induction and/or
downstream IFN receptor (IFNAR) signaling, this could
lead to suppression of both type I IFN production as
well as downstream IRG induction. Such suppression is
caused by the interaction of GRIP1/NCOA2 –a cofactor
of GC signaling– with IRF3 and IRF9, and subsequent
interference between GR signaling and TLR signaling
and IFNAR signaling, respectively [6,7]. Additionally, it
was demonstrated that GCs are able to induce expres-
sion of SOCS1 [16], a well-known inhibitor of JAK-
STAT signaling, including type I IFN signaling [17].
Because both TLR and JAK-STAT signaling are impli-
cated in the regulation of type I IFN activity in RA
[18,19], this may be an additional mechanism of the ob-
served prednisone-related IRG suppression. However,
our study was not aimed at unravelling the mechanisms
of GC-mediated type I IFN suppression, which is the
objective of future studies.
Our observations raise questions regarding the rela-
tion between high baseline IRG expression and a poor
response to RTX. It is yet unclear whether high IRG ex-
pression is (in)directly causative for RTX non-response
or whether it is a related epiphenomenon. In the case of
a causative relation between high baseline IRG expres-
sion and RTX non-response, it would be expected that
prednisone use, as a suppressor of IRG expression,
would lead to more responders. This was not observed
in our cohort, as reflected by the described absence of a
direct relation between prednisone use and the clinical
response to RTX [3]. Moreover, we did not observe any
bias in clinical parameters between the subgroups ofprednisone use and RTX response. Since the numbers
of patients per subgroup are rather small, this could be
due to a lack of power. However, our data indicate that
the difference in prediction accuracy between PREDN−
and PREDN+ patients is selectively due to prednisone-
related IRG suppression in RTX non-responders,
resulting in false-positive good responders in the
PREDN+ group, whereas responders are almost per-
fectly distinguishable from non-responders in the
PREDN− group. Altogether, these observations indicate
that IFNhigh patients using prednisone might appear as
IFNlow patients due to the prednisone-related IRG sup-
pression, but still turn out to be non-responders to
RTX. This would in turn imply that the relation be-
tween high IRG expression and RTX non-responders is
not a directly causative one.
Besides the association between baseline IRG expres-
sion and RTX response, there are indications of phar-
macodynamic differences during RTX therapy as well.
Vosslamber et al. provided evidence that RTX re-
sponders, that is, patients with low baseline IRG expres-
sion, exhibited IRG upregulation after three months of
therapy, whereas RTX non-responders did not [20],
suggesting that type I IFN dynamics is related to the
clinical outcome of RTX treatment. It was hypothesized
that high IRG expression before RTX treatment could
reflect an over-stimulated type I IFN system, incapable
of further inducing the IRG expression that would be
essential to reach a favorable response to RTX. With re-
gard to prednisone interference, one could speculate
that this process of pathway saturation, possibly caused
by extensive negative feedback or shortage of signaling
proteins, could be synergistically enhanced by prednis-
one. This would then result in the absence of IRG in-
duction during RTX therapy, despite relatively low IRG
expression at baseline. Interestingly, the majority of pa-
tients in the study of Vosslamber et al. was using pred-
nisone (82%), and patients were allowed to continue
using it during RTX therapy [20]. Moreover, the ob-
served pharmacological induction of IRG expression
during RTX therapy was described to be irrespective of
clinical parameters, such as prednisone use [20], sug-
gesting it was persistent despite GC interference. This
could in turn imply that the IRG expression as induced
during RTX treatment occurs via a different mechanism
than the IRG expression at baseline, which has appeared
sensitive to prednisone interference.
Our data might also be useful for other treatment reg-
imens, as the relation between the IFN system and
treatment response does not seem to be restricted to
RTX. For example, for anti-TNF therapy with inflixi-
mab, the dynamics of IRG expression appeared to be re-
lated to the clinical response, as non-responders
showed an IRG upregulation during treatment whereas
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genome-wide expression study revealed that high IRG
expression before the start of treatment with toci-
lizumab, an IL-6R blocker, is associated with a favorable
response [23]. The response patterns observed for these
biologics are not in line with that for RTX. Although
the clinical relevance for these results needs to be vali-
dated in independent studies, it may indicate that the
status of the IFN system might have different clinical
consequences in RA depending on the specific biologic
that is used, that is, the immune pathway that is modu-
lated. Our findings on in vivo interference of the IFN-
system by prednisone may be equally relevant for the
other biologic therapies and indications that are charac-
terized by differential IFN activity. In these cases separ-
ate analysis of PREDN− and PREDN+ patients could
provide supportive value for these claims.
Conclusions
In conclusion, we have demonstrated that type I IFN ac-
tivity in RA patients is suppressed in prednisone users.
Consequently, our findings reveal that the IFN-score
based model to predict the clinical outcome of RTX
treatment can be optimized by implementation of pred-
nisone use. This result provides an accurate system for
response prediction of RTX, thereby taking the paradigm
of personalized medicine one step further.
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